婴儿利什曼原虫LPG3蛋白联合皂苷佐剂疫苗抗内脏利什曼病研究
该研究在小鼠模型中评价天然及重组婴儿利什曼原虫LPG3蛋白联合皂苷或弗氏不完全佐剂的免疫效果。LPG3-SAP疫苗使脾和肝寄生虫负荷均降低约98%,并诱导Th1/Th17应答及IL-10产生;重组LPG3-SAP与天然蛋白结果相似,被认为可进入犬和人模型后续试验。
要点
- LPG3-SAP使小鼠脾、肝寄生虫负荷均降低约98%,并诱导Th1/Th17应答。
- LPG3-IFA仅使脾寄生虫负荷降低96%,肝寄生虫负荷未见显著下降。
- 重组LPG3-SAP与天然LPG3-SAP结果相似,具备后续犬和人模型试验潜力。
核心结论
- 重组LPG3-SAP疫苗在小鼠模型中显示抗婴儿利什曼原虫感染潜力,可考虑进入犬和人模型后续试验。
研究设计与样本
- 在BALB/c小鼠中评价天然及重组婴儿利什曼原虫LPG3蛋白联合皂苷(SAP)或弗氏不完全佐剂(IFA)的免疫效果。
主要发现
- LPG3-IFA组脾寄生虫负荷较PBS对照组降低96%,但肝寄生虫负荷未见显著下降。
- LPG3-SAP组脾和肝寄生虫负荷均降低约98%,伴Th1/Th17应答及AgLc刺激脾细胞产生IL-10。
- 重组LPG3-SAP与天然LPG3-SAP疫苗结果相似。
临床怎么用
- 原文为小鼠模型研究,尚未提供犬或人体的应用推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Visceral leishmaniasis (VL) is a serious neglected tropical disease that affects humans and dogs in urban areas. There are no vaccines against human VL, and few licensed canine VL vaccines are currently available, which instigates the search for new antigens and vaccine formulations with prophylactic potential against VL in these hosts. In this study, we evaluated the immunization using the native and recombinant Leishmania infantum chagasi (L. chagasi) lipophosphoglycan-3 (LPG3) and the adjuvants saponin (SAP) and incomplete Freund adjuvant (IFA) against L. chagasi infection in BALB/c mice. The native LPG3 vaccine was immunogenic, inducing splenic IFN-γ and IL-10 production, and mixed Th1/Th2 response when associated with IFA. However, only mice vaccinated with LPG3-IFA presented a reduction in the splenic parasite load (96% in comparison to the PBS control group), but without a significant reduction in the hepatic parasitism. On the other hand, mice immunized with the LPG3-SAP vaccine presented a reduction of approximately 98% in both splenic and hepatic parasite load, accompanied by a Th1/Th17 response and IL-10 production by L. chagasi antigen (AgLc)-stimulated splenic cells. Importantly, vaccination with recombinant LPG3 (rLPG3)-SAP presented similar results to the native LPG3-SAP vaccine. Therefore, the rLPG3-SAP vaccine is qualified to be used in future tests in canine and human models, considering the technical and economic advantages of the recombinant protein production compared to the native protein and the results obtained in the murine model.
引用
- de Oliveira Emerick S, Vieira de Carvalho T, Meirelles Miranda B, et al. Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis. Vaccine. 2020. PMID: 33309484. doi:10.1016/j.vaccine.2020.11.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。